文献速递神经核医学核素与放射性配体治疗

肽受体放射性核素治疗高级别胶质瘤的可行性与治疗潜力

Feasibility and Therapeutic Potential of Peptide Receptor Radionuclide Therapy for High-Grade Gliomas.
PubMed 文献 · Clin Nucl Med · 2021-01-01

这项前瞻性初步研究纳入16例无法手术或标准治疗难治的高级别胶质瘤患者,所有患者均检查肿瘤生长抑素受体表达,接受1至4周期静脉177Lu-DOTATATE治疗。主要终点为肽受体放射性核素治疗后的影像学反应,次要终点为采用Karnofsky功能状态评分和东部肿瘤协作组评分评估的生活质量改善。结果显示完全缓解12.5%(n=2)、部分缓解31.25%(n=5)、疾病稳定18.7%(n=3)、疾病进展37.5%(n=6),治疗前后Karnofsky功能状态评分和东部肿瘤协作组评分均未改善(P>0.05)。

要点

  • 治疗前后Karnofsky功能状态评分和东部肿瘤协作组评分均未改善(P>0.05)。
  • 作者建议在更同质、功能状态更好的患者群体中进一步评估。

核心结论

  • 初步结果提示177Lu-DOTATATE肽受体放射性核素治疗可能对高级别胶质瘤(III-IV级)患者有积极作用。
  • 该方法应在更同质且功能状态更有利的患者群体中进一步评估。

研究设计与样本

  • 前瞻性初步研究,纳入16例无法手术或标准常规治疗难治的高级别胶质瘤患者。
  • 所有患者检查肿瘤生长抑素受体表达,接受1至4周期静脉177Lu-DOTATATE治疗。
  • 主要终点为肽受体放射性核素治疗后的影像学反应,次要终点为采用Karnofsky功能状态评分和东部肿瘤协作组评分评估的生活质量改善。

主要发现

  • 共16例受试者(10男6女),平均年龄55.68±13.17岁(范围26-73岁)。
  • 8例为新诊断高级别胶质瘤,8例为复发肿瘤。
  • 治疗反应:完全缓解12.5%(n=2),部分缓解31.25%(n=5),疾病稳定18.7%(n=3),疾病进展37.5%(n=6)。
  • 治疗前后Karnofsky功能状态评分和东部肿瘤协作组评分均未改善(P>0.05)。
  • 随访时间1个月至26个月(中位3个月)。

临床怎么用

  • 对于无法手术或标准治疗难治且生长抑素受体表达的高级别胶质瘤患者,177Lu-DOTATATE可作为探索性治疗选择。
  • 治疗决策需结合患者功能状态,本研究提示功能状态较差者可能难以从该治疗中获得生活质量改善。

局限性

  • 本研究为初步小样本(16例)研究,结果需在更同质且功能状态更好的患者群体中进一步验证。
  • 随访时间较短(中位3个月),长期疗效和安全性未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This pilot study tested the principle that 177Lu-DOTATATE may be applied to patients with high-grade gliomas (HGGs) that are either inoperable or refractory to the standard conventional treatments and also assessed whether this approach could be a viable therapeutic plan in this dilemma. METHODS: In this prospective study, 16 subjects experiencing HGGs that were either inoperable or refractory to the standard conventional treatments were included. All the patients checked for somatostatin receptor expression on the tumors. The patients were treated with 1 to 4 cycles of IV 177Lu-DOTATATE. The primary end point was radiological response after peptide receptor radionuclide therapy, and the secondary end point was improved quality of life using Karnofsky Performance Score and Eastern Cooperative Oncology Group score. RESULTS: In total, 16 subjects (10 males and 6 females) with a mean age of 55.68 ± 13.17 years (26-73 years) participated in the study. Of them, 8 patients were new HGG cases, and 8 patients had recurrent tumors. The participants' responses to treatments were complete remission in 12.5% of (n = 2), partial remission in 31.25% (n = 5), disease stability in 18.7% (n = 3), and disease progression in 37.5% (n = 6). In total, pretreatment and posttreatment Karnofsky Performance Score and Eastern Cooperative Oncology Group scores did not improved (P > 0.05). The patients were followed up from 1 month to 26 months (median, 3 months). CONCLUSIONS: This preliminary result suggests that peptide receptor radionuclide therapy using 177Lu-DOTATATE may be associated with positive effects in patients with HGGs (grade III-IV). However, this approach should be evaluated in a more homogeneous group of patients with more favorable performance status.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nemati R, Shooli H, Rekabpour SJ, et al. Feasibility and Therapeutic Potential of Peptide Receptor Radionuclide Therapy for High-Grade Gliomas. Clin Nucl Med. 2021. PMID: 33782298. doi:10.1097/RLU.0000000000003599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。